$XSNX
NovAccess Global Inc

2023 Q2 Form 10-Q Financial Statement

#000118518523000522 Filed on May 15, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue $0.00 $0.00 $0.00
YoY Change
Gross Profit $0.00 $0.00 $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $444.5K $1.014M $381.4K
YoY Change 62.35% 165.83% 35.59%
% of Gross Profit
Research & Development $40.16K $41.04K $45.52K
YoY Change -21.46% -9.85%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $484.6K $1.055M $427.0K
YoY Change 49.16% 147.1% 51.77%
Operating Profit -$484.6K -$1.055M -$426.9K
YoY Change 49.16% 147.1%
Interest Expense $295.1K $262.2K -$748.0K
YoY Change -43.36% -135.05% 92.85%
% of Operating Profit
Other Income/Expense, Net -$295.0K $1.509M -$802.8K
YoY Change -841.04% -287.93%
Pretax Income -$779.6K $453.8K -$1.230M
YoY Change 173.45% -136.9% 83.77%
Income Tax
% Of Pretax Income
Net Earnings -$779.6K $453.8K -$1.230M
YoY Change 173.46% -136.9% 83.77%
Net Earnings / Revenue
Basic Earnings Per Share -$0.04 $0.02 -$0.08
Diluted Earnings Per Share -$0.04 $0.01 -$79.96K
COMMON SHARES
Basic Shares Outstanding 21.19M shares 20.83M shares 15.38M shares
Diluted Shares Outstanding 21.21M shares 39.68M shares 15.38M shares

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $61.46K $21.99K $61.61K
YoY Change -31.67% -64.31% 180.05%
Cash & Equivalents $61.46K $21.99K $61.61K
Short-Term Investments
Other Short-Term Assets $49.58K $81.47K $21.90K
YoY Change -50.17% 272.01%
Inventory
Prepaid Expenses $49.58K $81.47K
Receivables
Other Receivables
Total Short-Term Assets $177.0K $103.5K $83.51K
YoY Change -6.55% 23.89% 279.59%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets -$3.00 -$1.00 $0.00
YoY Change 0.0%
TOTAL ASSETS
Total Short-Term Assets $177.0K $103.5K $83.51K
Total Long-Term Assets -$3.00 -$1.00 $0.00
Total Assets $177.0K $103.5K $83.51K
YoY Change -6.55% 23.89% 279.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $520.3K $446.8K $361.9K
YoY Change 131.4% 23.46% 43.72%
Accrued Expenses $25.82K $5.570K $117.1K
YoY Change -72.1% -95.24% -1.64%
Deferred Revenue
YoY Change
Short-Term Debt $21.00K $21.00K $578.4K
YoY Change 75.0% -96.37% 1463.14%
Long-Term Debt Due $1.874M $1.745M $0.00
YoY Change -100.0%
Total Short-Term Liabilities $6.410M $5.830M $4.516M
YoY Change 38.54% 29.1% 72.76%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $165.9K
YoY Change -100.0% -100.0% 44.24%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $165.9K
YoY Change -100.0% -100.0% 44.24%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.410M $5.830M $4.516M
Total Long-Term Liabilities $0.00 $0.00 $165.9K
Total Liabilities $6.410M $5.830M $4.682M
YoY Change 33.75% 24.53% 71.56%
SHAREHOLDERS EQUITY
Retained Earnings -$65.13M -$64.36M
YoY Change 4.85%
Common Stock $43.66M $43.62M
YoY Change 1.06%
Preferred Stock $4.747M $4.211M
YoY Change 0.0%
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$6.233M -$5.727M -$4.598M
YoY Change
Total Liabilities & Shareholders Equity $177.0K $103.5K $83.51K
YoY Change -6.55% 23.89% 279.59%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$779.6K $453.8K -$1.230M
YoY Change 173.46% -136.9% 83.77%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$113.3K -$197.2K -$248.8K
YoY Change -57.59% -20.73% 51.89%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $75.00K
YoY Change -50.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 152.8K 180.2K 285.7K
YoY Change -48.3% -36.91% 60.53%
NET CHANGE
Cash From Operating Activities -113.3K -197.2K -248.8K
Cash From Investing Activities
Cash From Financing Activities 152.8K 180.2K 285.7K
Net Change In Cash 39.47K -16.95K 36.92K
YoY Change 39.37% -145.91% 160.18%
FREE CASH FLOW
Cash From Operating Activities -$113.3K -$197.2K -$248.8K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-29621
dei Entity Registrant Name
EntityRegistrantName
NovAccess Global Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
CO
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-1384159
dei Entity Address Address Line1
EntityAddressAddressLine1
8584 E. Washington Street #127
dei Entity Address City Or Town
EntityAddressCityOrTown
Chagrin Falls
dei Entity Address State Or Province
EntityAddressStateOrProvince
OH
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
44023
dei City Area Code
CityAreaCode
213
dei Local Phone Number
LocalPhoneNumber
642-9268
dei Security12b Title
Security12bTitle
None
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
21185028 shares
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21991 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
64251 usd
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
81468 usd
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
60650 usd
CY2023Q1 us-gaap Assets
Assets
103459 usd
CY2022Q3 us-gaap Assets
Assets
124901 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
446828 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
375682 usd
CY2023Q1 us-gaap Interest Payable Current
InterestPayableCurrent
1654274 usd
CY2022Q3 us-gaap Interest Payable Current
InterestPayableCurrent
1486561 usd
CY2023Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1769259 usd
CY2022Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1440012 usd
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
181217 usd
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
186217 usd
CY2023Q1 us-gaap Short Term Borrowings
ShortTermBorrowings
21000 usd
CY2022Q3 us-gaap Short Term Borrowings
ShortTermBorrowings
12500 usd
CY2023Q1 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
157807 usd
CY2022Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
340503 usd
CY2023Q1 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
1745073 usd
CY2022Q3 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
1266627 usd
CY2023Q1 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
0 usd
CY2022Q3 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
2132 usd
CY2023Q1 us-gaap Notes Payable Current
NotesPayableCurrent
12500 usd
CY2022Q3 us-gaap Notes Payable Current
NotesPayableCurrent
10368 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
5830151 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
4777967 usd
CY2023Q1 us-gaap Liabilities
Liabilities
5830151 usd
CY2022Q3 us-gaap Liabilities
Liabilities
4777967 usd
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
25000 shares
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
25000 shares
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
6 usd
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
6 usd
CY2023Q1 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2022Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2000000000 shares
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2000000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21185028 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21185028 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18669507 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18669507 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
43623184 usd
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
43225982 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
6047212 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
5340398 usd
CY2023Q1 xsnx Additional Paid In Capital Common Stock Warrants
AdditionalPaidInCapitalCommonStockWarrants
4747108 usd
CY2022Q3 xsnx Additional Paid In Capital Common Stock Warrants
AdditionalPaidInCapitalCommonStockWarrants
4747108 usd
CY2023Q1 us-gaap Additional Paid In Capital Preferred Stock
AdditionalPaidInCapitalPreferredStock
4210960 usd
CY2022Q3 us-gaap Additional Paid In Capital Preferred Stock
AdditionalPaidInCapitalPreferredStock
4210960 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-64355162 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-62177520 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-5726692 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-4653066 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
103459 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
124901 usd
CY2023Q1 us-gaap Revenues
Revenues
0 usd
CY2022Q1 us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
0 usd
CY2022Q1 us-gaap Cost Of Revenue
CostOfRevenue
0 usd
us-gaap Cost Of Revenue
CostOfRevenue
0 usd
us-gaap Cost Of Revenue
CostOfRevenue
0 usd
CY2023Q1 us-gaap Gross Profit
GrossProfit
0 usd
CY2022Q1 us-gaap Gross Profit
GrossProfit
0 usd
us-gaap Gross Profit
GrossProfit
0 usd
us-gaap Gross Profit
GrossProfit
0 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
41036 usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
45516 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
76000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
87915 usd
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1013952 usd
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
381428 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1496106 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
661358 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
1054988 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
426944 usd
us-gaap Operating Expenses
OperatingExpenses
1572106 usd
us-gaap Operating Expenses
OperatingExpenses
749273 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1054988 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-426944 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1572106 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-749273 usd
CY2023Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
1825730 usd
CY2022Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-492425 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-255854 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-33399 usd
CY2023Q1 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
138863 usd
CY2022Q1 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
0 usd
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
138863 usd
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
96205 usd
CY2023Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2022Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-54813 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-54813 usd
CY2023Q1 us-gaap Gains Losses On Restructuring Of Debt
GainsLossesOnRestructuringOfDebt
-193625 usd
CY2022Q1 us-gaap Gains Losses On Restructuring Of Debt
GainsLossesOnRestructuringOfDebt
0 usd
us-gaap Gains Losses On Restructuring Of Debt
GainsLossesOnRestructuringOfDebt
74125 usd
us-gaap Gains Losses On Restructuring Of Debt
GainsLossesOnRestructuringOfDebt
0 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
262216 usd
CY2022Q1 us-gaap Interest Expense
InterestExpense
255603 usd
us-gaap Interest Expense
InterestExpense
562670 usd
us-gaap Interest Expense
InterestExpense
631813 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1508752 usd
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-802841 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-605536 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-623820 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
453764 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-1229785 usd
us-gaap Net Income Loss
NetIncomeLoss
-2177642 usd
us-gaap Net Income Loss
NetIncomeLoss
-1373093 usd
CY2023Q1 xsnx Deemed Dividend On Warrant Repricing
DeemedDividendOnWarrantRepricing
44241 usd
CY2022Q1 xsnx Deemed Dividend On Warrant Repricing
DeemedDividendOnWarrantRepricing
0 usd
xsnx Deemed Dividend On Warrant Repricing
DeemedDividendOnWarrantRepricing
44241 usd
xsnx Deemed Dividend On Warrant Repricing
DeemedDividendOnWarrantRepricing
0 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
409523 usd
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1229785 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2221883 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1373093 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.02
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.01
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.08
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20698747 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15379289 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19832524 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14914920 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39680653 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15379289 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19832524 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14914920 shares
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-3928094 usd
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
184475 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
119480 usd
us-gaap Proceeds From Loans
ProceedsFromLoans
75000 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
170200 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
8000 usd
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
104813 usd
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
111000 usd
us-gaap Net Income Loss
NetIncomeLoss
-1373093 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-4598219 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-4653066 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
259702 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
50000 usd
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
82500 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
563314 usd
us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
148500 usd
us-gaap Net Income Loss
NetIncomeLoss
-2177642 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-5726692 usd
us-gaap Net Income Loss
NetIncomeLoss
-2177642 usd
us-gaap Net Income Loss
NetIncomeLoss
-1373093 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
432083 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
479689 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-255854 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-33399 usd
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
138863 usd
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
96205 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-54813 usd
us-gaap Share Based Compensation
ShareBasedCompensation
711814 usd
us-gaap Share Based Compensation
ShareBasedCompensation
53619 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
259702 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
73861 usd
us-gaap Debt Related Commitment Fees And Debt Issuance Costs
DebtRelatedCommitmentFeesAndDebtIssuanceCosts
82500 usd
us-gaap Debt Related Commitment Fees And Debt Issuance Costs
DebtRelatedCommitmentFeesAndDebtIssuanceCosts
79043 usd
us-gaap Interest And Debt Expense
InterestAndDebtExpense
0 usd
us-gaap Interest And Debt Expense
InterestAndDebtExpense
546 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
20818 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-5568 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
71147 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
39700 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
167713 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
210216 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-356510 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-438844 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
50000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
175200 usd
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
0 usd
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
3151 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
340000 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
213000 usd
us-gaap Payments For Repurchase Of Preferred Stock And Preference Stock
PaymentsForRepurchaseOfPreferredStockAndPreferenceStock
5000 usd
us-gaap Payments For Repurchase Of Preferred Stock And Preference Stock
PaymentsForRepurchaseOfPreferredStockAndPreferenceStock
50000 usd
us-gaap Proceeds From Loans
ProceedsFromLoans
8500 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
0 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
2316 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
-79250 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
-94250 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
314250 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
319785 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-42260 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-119059 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
64251 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
180668 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21991 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61609 usd
us-gaap Interest Paid Net
InterestPaidNet
17711 usd
us-gaap Interest Paid Net
InterestPaidNet
71245 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
800 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Interest Costs Capitalized
InterestCostsCapitalized
0 usd
us-gaap Interest Costs Capitalized
InterestCostsCapitalized
546 usd
us-gaap Other Significant Noncash Transaction Value Of Consideration Given1
OtherSignificantNoncashTransactionValueOfConsiderationGiven1
0 usd
us-gaap Other Significant Noncash Transaction Value Of Consideration Given1
OtherSignificantNoncashTransactionValueOfConsiderationGiven1
200000 usd
CY2020Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-1,000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration:underline">Use of Estimates</span></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the accompanying consolidated financial statements. Significant estimates made in preparing these consolidated financial statements include the estimate of the deferred tax valuation allowance, the fair value of stock options, and derivative liabilities. Actual results could differ from those estimates.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
409523 usd
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1229785 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2221883 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1373093 usd
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20698747 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15379289 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19832524 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14914920 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39680653 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15379289 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19832524 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14914920 shares
CY2022Q3 us-gaap Derivative Assets
DerivativeAssets
0 usd
CY2022Q3 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
1207403 usd
CY2022Q3 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
232609 usd
CY2022Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
1440012 usd
CY2023Q1 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
1211565 usd
CY2023Q1 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
557694 usd
CY2023Q1 us-gaap Derivative Liabilities
DerivativeLiabilities
1769259 usd
CY2021Q3 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
2926622 usd
CY2022 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
875348 usd
CY2022 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Gain Loss Included In Earnings
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings
-2084242 usd
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
-277716 usd
CY2022Q3 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
1440012 usd
us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
212256 usd
us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Gain Loss Included In Earnings
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings
255854 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
-138863 usd
CY2023Q1 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
1769259 usd
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2000000000 shares
CY2020Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-1,000
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
us-gaap Stock Issued During Period Shares Period Increase Decrease
StockIssuedDuringPeriodSharesPeriodIncreaseDecrease
2515521 shares
us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
1490521 shares
us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
500000 shares
us-gaap Stock Issued During Period Shares Period Increase Decrease
StockIssuedDuringPeriodSharesPeriodIncreaseDecrease
3119643 shares
us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
1502670 shares
us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
265973 shares
us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
300000 shares
us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
250000 shares
CY2023Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
1902880 usd
CY2023Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
157807 usd
CY2023Q1 us-gaap Convertible Debt
ConvertibleDebt
1745073 usd
CY2013Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
12000 usd
CY2013Q4 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
4.5
CY2013Q4 us-gaap Debt Instrument Fee Amount
DebtInstrumentFeeAmount
1200 usd
CY2022Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.5
CY2023Q2 us-gaap Debt Default Longterm Debt Amount
DebtDefaultLongtermDebtAmount
271551 usd
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.175
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3542857 shares
CY2022Q3 us-gaap Debt Instrument Maturity Date Description
DebtInstrumentMaturityDateDescription
The loan terms required repayment of all amounts outstanding under the loan on the earlier of: (a) October 31, 2022 or (b) the receipt by the Company of debt or equity financing of $3 million
CY2022Q4 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2023-04-30
CY2023Q1 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
8500 usd
CY2022Q2 xsnx Class Of Warrant Or Rights Granted
ClassOfWarrantOrRightsGranted
1000000 shares
CY2022Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.01
CY2023Q1 xsnx Class Of Warrant Or Rights Granted
ClassOfWarrantOrRightsGranted
1000000 shares
CY2023Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.2
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
148500 usd
CY2023Q1 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
557694 usd
CY2022Q3 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
232609 usd
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1500000 shares
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
44241 usd
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2000000000 shares
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
0.00001
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2000000 shares
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.01
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0032 pure
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.46 pure
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage
SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
1 pure
CY2022Q3 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
36815 usd
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1654274 usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0368 pure
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.4679 pure
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2000000 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.01
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3542857 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.175
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5542857 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.115
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5570 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4370 usd
CY2023Q1 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
159506 usd
CY2022Q3 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
94251 usd
CY2023Q1 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
7367 usd
CY2022Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
4740 usd
CY2023Q1 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
485421 usd
CY2022Q3 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
344983 usd
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
40402 usd
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
40402 usd
CY2023Q1 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
69133 usd
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1486561 usd
CY2022 us-gaap Interest Paid
InterestPaid
583 usd
CY2021Q4 us-gaap Proceeds From Other Debt
ProceedsFromOtherDebt
25000 usd
CY2021Q4 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
125000 shares
CY2021Q4 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-37500 usd
CY2022 us-gaap Interest Expense Debt
InterestExpenseDebt
226 usd
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-54813 usd
CY2022Q1 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
1502670 shares
CY2022Q1 us-gaap Preferred Stock Convertible Conversion Price
PreferredStockConvertibleConversionPrice
0.35
CY2022Q1 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
525934 usd
CY2022Q1 xsnx Common Stock Outstanding Percentage
CommonStockOutstandingPercentage
0.10 pure
CY2022Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
250000 usd
CY2023Q1 us-gaap Preferred Stock Redemption Amount
PreferredStockRedemptionAmount
95000 usd
CY2023Q1 us-gaap Proceeds From Other Debt
ProceedsFromOtherDebt
8500 usd
CY2022Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
12500 usd
CY2022Q1 us-gaap Investment Owned Balance Shares
InvestmentOwnedBalanceShares
24400 shares
us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
1502670 shares
xsnx Common Stock Outstanding Percentage
CommonStockOutstandingPercentage
0.10 pure
CY2022Q1 us-gaap Stock Issued During Period Shares Acquisitions
StockIssuedDuringPeriodSharesAcquisitions
7500000 shares
CY2021Q4 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
25000 usd
CY2021Q4 us-gaap Debt Instrument Maturity Date Description
DebtInstrumentMaturityDateDescription
The notes were payable on demand with a five business-day written notice
CY2021Q4 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.10 pure
CY2022Q1 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
125000 shares
CY2022Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-17313 usd
CY2020Q3 xsnx Agreement Monthly Amount
AgreementMonthlyAmount
30000 usd
CY2020Q3 xsnx Agreement Term
AgreementTerm
P3Y
CY2022 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
40000 usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Entity Central Index Key
EntityCentralIndexKey
0001039466
dei No Trading Symbol Flag
NoTradingSymbolFlag
true
dei Security Exchange Name
SecurityExchangeName
NONE

Files In Submission

Name View Source Status
xsnx-20230331_cal.xml Edgar Link unprocessable
0001185185-23-000522-index-headers.html Edgar Link pending
0001185185-23-000522-index.html Edgar Link pending
0001185185-23-000522.txt Edgar Link pending
0001185185-23-000522-xbrl.zip Edgar Link pending
ex_519542.htm Edgar Link pending
ex_519543.htm Edgar Link pending
ex_519544.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
novaccess20230331_10q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
novaccess20230331_10q_htm.xml Edgar Link completed
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
xsnx-20230331.xsd Edgar Link pending
xsnx-20230331_def.xml Edgar Link unprocessable
xsnx-20230331_pre.xml Edgar Link unprocessable
xsnx-20230331_lab.xml Edgar Link unprocessable